[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholangiopancreatography-endoscopic-retrograde\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholangiopancreatography-endoscopic-retrograde":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100609228","eeg-and-pain-monitor-data-under-anesthesia-to-study-pharmacodynamic-effects-of-opioids-and-sedatives-100609228",false,"NCT07211828","EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and Sedatives","Pharmacodynamic Effects of Propofol and Alfentanil on EEG During Endoscopic Retrograde Cholangiopancreatography (ERCP)","SED-ERCP","Inclusion Criteria:\n\n* Patients who under go ERCP who require general anesthesia\n\nExclusion Criteria:\n\n* ASA\\> or = 4 , vulnerable groups such as prisoners, patients with physical or mental disabilities and HIV carriers","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Recording and analyzing electroencephalogram (EEG) and continuous pain monitor data under anesthesia in order to investigating the pharmacodynamic effects of opioids and sedatives.",[27,28,29],"Sedation and Analgesia","Cholangiopancreatography, Endoscopic Retrograde","Anesthesia, General",[31,32,33,34],"sedation","phramacodynamics","opioid","ERCP","RECRUITING","2026-03-24",{"date":38,"type":39},"2026-03-27","ACTUAL",{"date":41,"type":39},"2025-10-10",{"date":43,"type":21},"2028-06-16",{"name":45,"class":46},"Chi Kwan Fung","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100458210","eus-guided-entero-biliary-anastomosis-for-therapeutic-access-in-benign-biliary-obstructions-100458210","NCT05246657","EUS-guided Entero-biliary Anastomosis for Therapeutic Access in Benign Biliary Obstructions","EUS-guided Entero-biliary Anastomosis as Fistulas for Therapeutic Access in Benign Biliary Obstructions Not Accessible by ERCP","ATENHEA","Inclusion Criteria:\n\n* • Consecutive patients ≥ 18 years old.\n\n  * Benign biliary obstruction.\n  * ERCP failed or where ERCP could not be performed due to surgically-altered anatomy\n\nExclusion Criteria:\n\n* • Refusal to sign the informed consent.\n\n  * Malignant biliary obstruction\n  * Coagulopathy (INR\\>1.5) or trombocytopenia (\\\u003C50,000 platelets\u002Fmm3) uncorrectable.\n  * Inability to tolerate the sedation necessary for the examination.\n  * Pregnancy or lactation.\n  * Unable to follow-up",{"count":57,"type":21},50,"OBSERVATIONAL","Background: Transpapillary EUS-BD (rendezvous\u002Fantegrade) is gaining acceptance in BBO. The potential of transmural EUS-BD (hepaticogastrostomy\u002Fcholedochoduodenostomy) in complex BBO warrants study.\n\nAims: To assess feasibility and efficacy of TEA using transmural covered self-expandable metal-stents (cSEMS) to provide interval biliary drainage and create TAF for biliary endotherapy under cholangioscopy or fluoroscopy in BBO not amenable to ERCP.",[28],"2025-03-10",{"date":63,"type":39},"2025-03-11",{"date":65,"type":39},"2021-06-01",{"date":67,"type":21},"2026-07-01",{"name":69,"class":46},"Hospital del Rio Hortega",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100564003","phase-2-efficacy-and-safety-of-parecoxib-vs-indomethacin-in-preventing-post-ercp-pancreatitis-100564003","NCT06623513","Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis","A Single-Center, Prospective, Randomized, Controlled, Exploratory Trial Comparing the Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis: The PRECISE Trail","PRECISE","Inclusion Criteria:\n\n* Age between 18 and 80 years.\n* Patients scheduled to undergo ERCP for conditions such as common bile duct stones, benign or malignant biliary strictures, cholangitis, suspected biliary tumors, unexplained jaundice, or pancreas divisum.\n\nExclusion Criteria:\n\n* Previous papillectomy.\n* Previous endoscopic sphincterotomy (EST) without planned pancreatic duct intervention.\n* Simple biliary stent removal or replacement without planned pancreatic duct intervention.\n* Biliary-duodenal fistula, post-biliary-duodenal anastomosis, or post-biliary-jejunal anastomosis.\n* Malignant tumor of the pancreatic head.\n* Currently or recently (within 1 week) suffering from acute pancreatitis.\n* Current or recent (within 1 week) use of NSAIDs.\n* Recent (within 2 weeks) or within 4 weeks prior to surgery, gastrointestinal bleeding or peptic ulcers.\n* History of significant adverse reactions to NSAIDs.\n* Renal insufficiency (creatinine clearance \\< 30 mL\u002Fmin).\n* Moderate to severe hepatic impairment (Child-Pugh score ≥ 7).\n* Severe cardiovascular or cerebrovascular disease.\n* Patients with psychiatric disorders.\n* Pregnant or breastfeeding patients.\n* Patients without a rectum.\n* Patients unwilling or unable to provide informed consent.","80 Years",{"count":80,"type":21},100,[82],"PHASE2","This study aims to evaluate the efficacy and safety of parecoxib versus indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). It is a single-center, prospective, randomized, controlled, exploratory trial. Participants will be randomly assigned to receive either parecoxib or indomethacin as a preventive treatment. The primary endpoint is to compare the efficacy of the two drugs in reducing the incidence of PEP. Secondary endpoints include the incidence of moderate to severe PEP and post-ERCP-related adverse events. This study will systematically assess the efficacy and safety of both drugs, providing preliminary data for future larger confirmatory trials.",[85,28],"Pancreatitis, Acute",[87,88,89,90,91],"Parecoxib","Indomethacin","Post-ERCP Pancreatitis","Efficacy","Safety","NOT_YET_RECRUITING","2024-09-29",{"date":95,"type":39},"2024-10-02",{"date":97,"type":21},"2024-10-01",{"date":99,"type":21},"2026-09-30",{"name":101,"class":46},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine"]